MEK inhibitors in RASopathies.
Christina Bergqvist, Pierre Wolkenstein
https://pubmed.ncbi.nlm.nih.gov/33395032/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-29
170
Participants Needed
132
Research Sites
N/A
Total Duration
This trial evaluates treatments for children and young adults aged 2 to 21 with newly diagnosed or untreated low-grade glioma LGG that does not have a BRAFV600E mutation or systemic neurofibromatosis type 1. The study aims to compare the effects of selumetinib, an oral drug that blocks enzymes needed for cell growth, with the standard chemotherapy regimen of carboplatin and vincristine. The main goal is to determine if selumetinib is as effective as the standard treatment in preventing disease events and to see if it improves quality of life. Participants are randomly assigned to one of two treatment groups. One group receives vincristine and carboplatin intravenously during an induction phase followed by maintenance cycles every 42 days for up to 8 cycles. The other group takes selumetinib orally twice daily in 28-day cycles for up to 27 cycles. Both groups undergo regular blood collection and MRI scans throughout treatment. The selumetinib group also has heart function evaluated by echocardiography at the start. During the study, participants will have assessments including visual acuity tests, motor function evaluations, quality of life and cognitive function questionnaires. Follow-up visits occur every 3 months for the first year, then every 6 months for years 2 and 3, and annually thereafter up to 10 years. The primary outcome measured is event-free survival over this period. The study also collects tumor and blood samples to explore genetic factors related to treatment response.
CONDITIONS
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Selumetinib sulfate (oral MEK inhibitor) | Carboplatin plus vincristine sulfate (standard chemotherapy) |
|---|---|---|
| What is it? | A targeted oral MEK inhibitor (selumetinib sulfate) being evaluated for children and young adults with specific types of low-grade glioma who have not received prior non-surgical therapies. | A standard chemotherapy regimen combining carboplatin (IV infusion) and vincristine sulfate (IV infusion), which is widely used to treat pediatric low-grade glioma. |
| Role in the trial | Evaluated as the primary investigational treatment, compared directly to standard chemotherapy. | Serves as the direct comparator arm to evaluate how selumetinib performs relative to current standard therapy. |
| Primary use or studied purpose | Studied for first-line therapy of non-NF1, non-BRAFV600E low-grade glioma in pediatric and young adult patients who have not received prior chemotherapy or radiation. | Standard first-line chemotherapy for pediatric low-grade glioma where surgery alone is not adequate. |
| How is it given or performed? | Selumetinib sulfate is taken by mouth as a capsule, with dosing as defined by body size. Duration and dosing are determined by the trial protocol. | Carboplatin and vincristine are administered by intravenous infusion on a schedule defined by the protocol, repeated in cycles over several months. |
| Published evidence or maturity | Supported by published phase 2 trial evidence suggesting activity in NF1 and non-NF1 pediatric low-grade gliomas, but long-term comparative results and overall survival impact in this population are not yet established. | Many years of published clinical experience, including prospective trials, establish carboplatin/vincristine as the benchmark chemotherapy for initial management when surgery is not sufficient. |
| Important risks or safety concerns | Known risks include rash, diarrhea, fatigue, and increased risk of infection; concern for cardiac and ophthalmologic (eye) adverse effects requires monitoring. Long-term safety beyond study duration is not fully established for this use. | Common risks involve bone marrow suppression (including low blood counts and risk of infection), peripheral neuropathy (nerve damage), nausea, and hair loss; long-term risks are well-characterized and monitored in clinical practice. |
| Important limitations or gaps | Selumetinib remains investigational for this use, with limited long-term follow-up and unknown overall survival benefit compared to standard chemotherapy. Not all glioma subtypes fully respond; access is limited to clinical trials. | Standard chemotherapy is associated with acute and chronic toxicity, often requires prolonged IV treatment, and not all patients achieve durable tumor control; some tumors may relapse or show progression despite therapy. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial assessment and tests including MRI, echocardiogram, ophthalmology exam, and blood tests
Duration - Up to 27 cycles (28 days each) for selumetinib or up to 8 cycles (42 days each) for chemotherapy
Participants receive either standard chemotherapy with carboplatin and vincristine through intravenous infusions or selumetinib taken orally twice daily. Blood samples and MRI scans are collected regularly during treatment. Heart function is checked at baseline for those on selumetinib.
Multiple visits for intravenous infusions or oral medication monitoring and imaging
Duration - Up to 10 years
After completing treatment, participants have scheduled follow-up visits to monitor health and disease status with imaging and clinical assessments.
Every 3 months for year 1, every 6 months for years 2-3, then annually
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Christina Bergqvist, Pierre Wolkenstein
https://pubmed.ncbi.nlm.nih.gov/33395032/Antje Arnold, Fausto Rodriguez, Charles G Eberhart...
https://pubmed.ncbi.nlm.nih.gov/32597469/National Cancer Institute (NCI)
Lead Sponsor